Table 3.

Adjusted between-group differences in clinical and symmetrical outcome improvements (post–pre), using baseline values as covariates.

Outcome measures	SRE group vs. CR group
10MWT, m/s	+0.05 (0.02–0.09) ** [0.243]
6MWT, m	+10.07 (1.98–18.15) * [0.195]
FAC	−0.10 (−0.33 to 0.13) [0.003]
FMA-LE	+1.68 (0.07–3.29) * [0.145]
BBS	−0.10 (−2.00 to 1.81) [0.011]
TSR	−0.26 (−0.42 to −0.11) ** [0.310]
SSR	−0.06 (−0.09 to −0.03) *** [0.437]

All analyses of covariance between-group differences were presented as mean difference (95% CI) [effect size: η2]; ^*p < 0.05, ^** p < 0.01, ^***p < 0.001, significant between-group differences.